Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Eligibility criteria updated to require at least one prior therapy after checkpoint inhibitors and to include relapse, replacing the previous requirement of at least two prior therapies and removing certain transplant/cytotoxic treatment exclusions.
    Difference
    0.3%
    Check dated 2026-03-11T23:37:39.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed; the earlier government funding/operating status notice (Revision: v3.4.1) has been removed. This is an administrative update and does not affect the study details.
    Difference
    0.4%
    Check dated 2026-02-11T11:52:16.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about potential delays due to government funding and the NIH Clinical Center status. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:28:41.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The additions and deletions are minor metadata and UI updates, including showing the glossary, new 'Last Update' fields, and a revision bump from v3.3.4 to v3.4.0, with some metadata items removed or reformatted. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:10:59.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Added Principal Investigator: Timothy Voorhees, MD, and protocol implementation contact details (CTO.Implementation@osumc.edu; 614-293-3717) for Ohio State University Comprehensive Cancer Center. Expanded the Locations/Recruiting sections to six sites with explicit Columbus, Ohio addresses and updated recruitment status.
    Difference
    1%
    Check dated 2026-01-21T04:24:21.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 updates the page from v3.3.3; no study content or eligibility details appear affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:44:16.000Z thumbnail image

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.